AOD-9604
$Human safety data exist; Obesity efficacy remains limited/contested
AOD-9604 is a modified fragment of human growth hormone intended to isolate fat-metabolism signaling without full hGH activity.
It has more human safety context than many gray-market peptides, but that is not the same thing as proven obesity-drug efficacy. Safety, metabolism, and weight-loss claims need to be separated.
Don't treat "Generally Recognized as Safe" or food-ingredient discussion as proof that injectable AOD is approved, effective, or equivalent to a prescription weight-loss medicine. Route note: AOD-9604 was orally administered in studies, but this should not be described as proven oral clinical efficacy or converted to SC dosing.
Classification details
- AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone.
- It was developed to investigate lipolytic signaling while avoiding the broader growth-promoting activity of full hGH.
- AOD-9604 is a modified hGH-fragment-derived compound, but it is not a growth hormone replacement or a GLP-1-like obesity drug. Its identity is tied to the lipolytic region of hGH, not to broad anabolic GH activity.
- Proposed mechanisms include lipolysis and reduced lipogenesis in experimental systems.
- It is not equivalent to full hGH, a GLP-1 drug, or a validated obesity treatment.
- The proposed mechanism is fat-metabolism modulation with reduced growth-promoting activity compared with full hGH. That mechanistic selectivity is the rationale, but it does not prove clinically meaningful fat loss.